scholarly journals Should Europe have a universal hepatitis B vaccination programme?

BMJ ◽  
2013 ◽  
Vol 347 (jul10 2) ◽  
pp. f4057-f4057 ◽  
Author(s):  
P. V. Damme ◽  
E. Leuridan ◽  
G. Hendrickx ◽  
A. Vorsters ◽  
H. Theeten ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Vaccination Programme ◽  
Hepatitis B Vaccination

An account of a pilot hepatitis B vaccination programme for high-risk individuals in Zürich

1983 ◽  
Vol 7 ◽  
pp. 85-92 ◽  
Author(s):  
P.J. Grob ◽  
M. Rickenbach ◽  
S. Wagner ◽  
J.O. Pelzer ◽  
Advisory Committee ◽  
...  
Keyword(s):  
High Risk ◽  
Hepatitis B ◽  
Vaccination Programme ◽  
Hepatitis B Vaccination

scholarly journals Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg

2006 ◽  
Vol 134 (4) ◽  
pp. 808-813 ◽  
Author(s):  
J. MOSSONG ◽  
L. PUTZ ◽  
S. PATINY ◽  
F. SCHNEIDER
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Vaccination Programme ◽  
Hepatitis A ◽  
Natural Infection ◽  
Hepatitis B Vaccination ◽  
Core Antigen ◽  
Substantial Impact ◽  
B Virus ◽  
The Impact

A prospective seroepidemiological survey was carried out in Luxembourg in 2000–2001 to determine the antibody status of the Luxembourg population against hepatitis A virus (HAV) and hepatitis B virus (HBV). One of the objectives of this survey was to assess the impact of the hepatitis B vaccination programme, which started in May 1996 and included a catch-up campaign for all adolescents aged 12–15 years. Venous blood from 2679 individuals was screened for the presence of antibodies to HAV antigen and antibodies to hepatitis B surface antigen (anti-HBs) using an enzyme immunoassay. Samples positive for anti-HBs were tested for antibody to hepatitis B core antigen (anti-HBc) using a chemiluminiscent microparticle immunoassay to distinguish between individuals with past exposure to vaccine or natural infection. The estimated age-standardized anti-HAV seroprevalence was 42·0% [95% confidence interval (CI) 39·8–44·1] in the population >4 years of age. Seroprevalence was age-dependent and highest in adult immigrants from Portugal and the former Yugoslavia. The age-standardized prevalence of anti-HBs and anti-HBc was estimated at 19·7% (95% CI 18·1–21·3) and 3·16% (95% CI 2·2–4·1) respectively. Anti-HBs seroprevalence exceeding 50% was found in the cohorts targeted by the routine hepatitis B vaccination programme, which started in 1996. Our study illustrates that most young people in Luxembourg are susceptible to HAV infection and that the hepatitis B vaccination programme is having a substantial impact on population immunity in children and teenagers.

Repeated-measures models to evaluate a hepatitis B vaccination programme

2001 ◽  
Vol 20 (6) ◽  
pp. 951-963 ◽  
Author(s):  
Didier Renard ◽  
Liesbeth Bruckers ◽  
Geert Molenberghs ◽  
Akke Vellinga ◽  
Pierre Van Damme
Keyword(s):  
Hepatitis B ◽  
Vaccination Programme ◽  
Repeated Measures ◽  
Hepatitis B Vaccination

Costs of running a universal adolescent hepatitis B vaccination programme

Vaccine ◽  
2005 ◽  
Vol 23 (48-49) ◽  
pp. 5624-5631 ◽  
Author(s):  
L.A. Wallace ◽  
D. Young ◽  
A. Brown ◽  
J.C. Cameron ◽  
S. Ahmed ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Vaccination Programme ◽  
Hepatitis B Vaccination

Seroepidemiology of Hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme

1999 ◽  
Vol 38 (3) ◽  
pp. 167-170 ◽  
Author(s):  
Faleh Z. AI-Faleh ◽  
Mohammad AI-Jeffri ◽  
Sami Ramia ◽  
Rashed AI-Rashed ◽  
Mohammad Arif ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Vaccination Programme ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document